Skip to Main Content

What’s a fair price for remdesivir? How do we know whether vaccines work? And does AI have a place in end-of-life care?

We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we dig into the long-awaited price for Gilead Sciences’ Covid-19 treatment and break down the disparate reactions from lawmakers, activists, and Wall Street analysts. Then, STAT’s Matthew Herper joins us to discuss some of the first detailed data on a potential vaccine for the novel coronavirus. Finally, we talk about a new use for AI: nudging clinicians to broach delicate conversations with patients about their end-of-life goals and wishes.


For more on what we cover, here’s the remdesivir news; here’s more on the vaccine data; here’s the story on AI; and here’s the latest in STAT’s coronavirus coverage.

We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on Apple PodcastsStitcherGoogle Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].


Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].

  • Dear All, some facts. Report fromKasturba Hospital Mumbai 13.6.2020
    30 oxygen intubated patients given Metadichol(r) (Nano Soma)
    At 7 days days 22 had recovered and tested negative
    At 10 days all remaining, except one, recovered too and tested negative.

    Report available upon request to Michael, acknowledging recipient, Dr P Raghavan at Nanorx.Inc. It worked well with SARS, EBola, MERS et al, now confirmed with SARS-CoV-2. The viron is the same shape and structure

    Not only had the virus been elliminated the inflammatory cytokine storm had been overcome. With the short time, the risk of neurlogical scarring permanence is redced. This an area of urgent research.

Comments are closed.